Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Reason February 2002 Mike Godwin	Prescription Panic How the anthrax scare challenged drug patents...
Managed Care November 2001 Frank Diamond	Overlooked in Cipro Hype: Other Anti-Anthrax Meds Federal health officials were slow to get out the word that doxycycline and penicillin are also approved for use against anthrax...
BusinessWeek June 24, 2010 Bliss & Decker	Ending the Silence of Generic Drugmakers The FTC says drugmakers are paying generic rivals not to compete.
Salon.com June 1, 2001 Daryl Lindsey	The AIDS-drug warrior Outspoken AIDS-drug activist Jamie Love says pharmaceutical companies must be forced to yield their patents to save hundreds of thousands of lives. Is he a visionary -- or a dangerous radical?
Chemistry World August 24, 2009 Sarah Houlton	Indian court dismisses Bayer's patent law case Bayer has failed in its attempt to stop Indian regulators giving marketing authorization to a generic version of its kidney cancer drug Nexavar (sorafenib), despite its 20 year patent having only been granted last year.
Salon.com March 19, 2001 Ben Barber	Fighting the plague The World Trade Organization steps into Africa's AIDS crisis, creating incentives for pharmaceutical companies to give some of their drugs away.
Salon.com May 1, 2001 Daryl Lindsey	Amy and Goliath A first-year law student brought a giant pharmaceutical to its knees. But will her victory for South Africa's AIDS sufferers deprive the world of new medicines?
The Motley Fool November 27, 2006 Brian Lawler	Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs.
The Motley Fool September 9, 2010 Jim Mueller	Today's Buy Opportunity: Teva Pharmaceutical Take advantage of this growing generic-drug maker.
The Motley Fool January 25, 2010 Brian Orelli	Pay-for-Delay Is Under the Spotlight It helps each side, but governments aren't thrilled with the idea.
Managed Care September 2006	Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association.
The Motley Fool June 25, 2009 Brian Orelli	Loss of a Settlement Option Earlier this month the Federal Trade Commission came out with a report arguing for limited patent protection for drugs made by biotech companies. Now it's ratcheting up its complaints about pharmaceutical and generic-drug companies as well.
The Motley Fool October 8, 2007 Brian Orelli	New FDA Regulations for Drugmakers To deal with a growing backlog of pending applications, the FDA plans to stop its first-come, first-served system.
Knowledge@Wharton	Drug Companies and the Patent Game: Fair Play or Foul? Is legal maneuvering a legitimate attempt by the big pharmaceutical companies to recover the huge costs of developing new drugs? Or are the brand-name firms inappropriately gaming the system for their own benefit, to the detriment of consumers and insurance companies?
The Motley Fool February 28, 2008 Brian Lawler	Benefiting From 2008's Generic Drugs While drug companies scramble to make up for lost revenue as their products are hit with patent expirations, other companies will benefit from the patent losses. Take a look at some winners and losers of drugs going off patent this year.
Chemistry World November 28, 2008 Matt Wilkinson	EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market.
Salon.com October 17, 2001 Laura Miller	Our first line of defense An expert on public health talks about what America needs to fight a bioterrorist attack, why we don't have it and how stocking up on cipro is a danger to everyone...
Managed Care February 2008 Martin Sipkoff	FDA Approach to Generics May Be a Mixed Blessing A recently announced initiative is supposed to speed approval of generic drugs, but does it address some fundamental flaws in the approval process?
Pharmaceutical Executive August 1, 2005 Jill Wechsler	Washington Report: Treating Patents It may seem unusual that a court ruling challenging patent protections is considered a victory for Big Pharma. But the decision was supported by pharmaceutical companies, along with the Justice Department, as a way to spur biomedical research and new-drug development.
Chemistry World July 10, 2009 Sarah Houlton	Branded drugs' competition-free days numbered Authorities in the US and Europe are to look carefully at the tactics pharmaceutical firms use to delay competition from generic versions of their branded drugs.
The Motley Fool January 31, 2008 Brian Orelli	Wyeth Calls Teva's Bluff Wyeth launches a generic version of its own heartburn drug.
The Motley Fool September 12, 2005 M.D. Mitchell	Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.
The Motley Fool November 30, 2006 Brian Lawler	Not Bad, Bayer The company's buyout of fellow German firm Schering AG looks like a boon to its bottom line. Investors, take note.
Managed Care March 2002	Will HHS Proposal Mean Better Info - Or Tighter Spin? The flow of medical information from government health agencies could very well wind up being one of the victims of the anthrax scare...
The Motley Fool April 22, 2011 Sean Williams	Pharma's Most Perilous Pipelines Patent expirations expose weaknesses for these Wall Street darlings.
Managed Care May 2006 John Carroll	Effective Ways To Increase Usage of Generics Generics is one of the few areas where insurance plans can economize effectively. BlueCross & BlueShield of North Carolina is one of many insurers that are changing members' and prescribers' behavior.
The Motley Fool March 13, 2008 Stephen Albainy-Jenei	Pfizer's Celebrex Aches and Pains The Court of Appeals for the Federal Circuit upholds a lower court's ruling that found Teva Pharmaceutical had infringed two of Pfizer's patents for Celebrex.
Pharmaceutical Executive October 1, 2010	Euro Soul-Searching on Competition A report by the European Commission aimed at exploring patent exploitation by Big Pharma winds up generating more angst than answers.
The Motley Fool September 23, 2008 Brian Lawler	Will Generic Biologics Get Special Treatment? While the rest of the market was lost in the financial meltdown, a little-noticed report discussing some of the biopharmaceutical bills going through Congress was released.
Pharmaceutical Executive November 1, 2005 Tamsen Valoir	Legal: State Compulsory Licenses The Supreme Court extended the power of eminent domain. Now states want to issue compulsory licenses under the same principle to control drug prices.
Bio-IT World November 2005 Patrick R. Scanlon	Patent Term Extension Primer U.S. patent law includes provisions for extending the patent term of medical devices and pharmaceuticals in instances when lengthy FDA approval is taking place during the term.
The Motley Fool January 31, 2007 Brian Lawler	Mylan on the Generic Attack Two new drug approvals for the generic drugmaker come in the midst of a changing regulatory environment. Investors, take note.
The Motley Fool March 31, 2010 Brian Orelli	When One Patent Means So Much The loss of patents on genes could have far-reaching consequences for drug companies.
The Motley Fool October 16, 2006 Brian Lawler	The Coming Generic Drug Boom Generic drugmakers are poised to profit from several key factors. Investors, take note.
The Motley Fool March 5, 2008 Brian Orelli	Yasmin Raises the Revenue Barr Barr gets a patent on Bayer's Yasmin overturned.
The Motley Fool December 30, 2008 Brian Orelli	2009's Generic Drugs: Who's at Risk The patent cliff is coming early for some drugmakers.
CIO August 1, 2003 Lawrence Rosen	Patents: An Expensive Tax on the CIO Software patents cost you money. Like taxes, they skim from your profit margins, but in this case the fees go to pay for other companies' intellectual property.
National Defense July 2009	Readers Sound Off on Recent Stories 7 Deadly Myth article draws comment.
The Motley Fool June 25, 2008 Brian Orelli	An Even More Complicated Patent Settlement Barr and Bayer settle their dispute about Yasmin. That's as simple as it gets.
Chemistry World September 2011	Column: In the pipeline Derek Lowe considers an increasingly popular business strategy in the drug industry, the much discussed 'pay for delay' deal
BusinessWeek September 16, 2010 Olga Kharif	Innovator: Andrew Thompson The engineer-turned-venture capitalist wants to transform your pills into miniature computers that can send out an alert when you miss a dose
Salon.com October 3, 2001 Pamela Weintraub	Be prepared? Taking precautions against bioterrorism may not be as futile as you think...
InternetNews September 3, 2009	Microsoft: Can't Our Patent Systems Get Along? Senior Microsoft legal eagle advocates "harmonization" of patent systems worldwide in blog post.
BusinessWeek July 9, 2007 Lorraine Woellert	Look Who's Fighting Patent Reform VCs, trade groups, and universities have taken up the fight against Big Tech's efforts to rewrite U.S. patent law.
IEEE Spectrum December 2007 Kirk Teska	The Foreign Patent Money Trap You may well need patents in many countries, but that doesn't mean you can afford them.
Bio-IT World June 17, 2004 Cathryn Campbell	Patent Plaintiff Perils Suing for patent infringement may seem rewarding, but you could lose even more.
Pharmaceutical Executive June 1, 2005 Peter J. Pitts	Opinion: Uncle Sam, MD Is having the government pursue a patent the best way of placing important discoveries in the public domain? It depends. Is putting the government in control of drug development in the best interests of public health? No.
The Motley Fool January 30, 2007 Brian Lawler	Par Passes the Generic Bar Par Pharmaceutical Companies gets approval to market another generic product, but the company still has to complete the restatement of its past financials. Investors, take note.
Chemistry World April 2, 2007	European Generics Suppliers Hit Generics drug manufacturers have lost a slice of their market with the reinstatement of a European patent covering Merck's multi-billion-dollar osteoporosis drug, Fosamax.
Pharmaceutical Executive October 1, 2005 Glass & Worrell	Whose Afraid of Authorized Generics Losing a patent challenge lets a generic competitor grab market share and slash branded profits. Sound scary? Ignoring authorized generics is worse.